{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:42:57Z","timestamp":1780566177563,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["KHRG-919864"],"award-info":[{"award-number":["KHRG-919864"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01571-8","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:51:49Z","timestamp":1757911909000},"page":"1693-1708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct05309785","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-8390","authenticated-orcid":false,"given":"Elias John","family":"Elenjickal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Gritsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita S.","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"1","key":"1571_CR1","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","volume":"13","author":"TA Mavrakanas","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023;13(1):15922.","journal-title":"Sci Rep"},{"key":"1571_CR2","doi-asserted-by":"crossref","unstructured":"Elenjickal EJ, Travlos CK, Luu J, Lemay S, Suri RS, Mavrakanas TA. Efficacy and safety of SGLT-2 inhibitors in patients with and without advanced CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2025;20(6):788\u2013809.","DOI":"10.2215\/CJN.0000000693"},{"issue":"10","key":"1571_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","volume":"54","author":"D Devineni","year":"2015","unstructured":"Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug\u2013drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2015;54(10):1027\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1571_CR4","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087\u201397.","journal-title":"Diabetologia"},{"issue":"1","key":"1571_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-019-0869-2","volume":"18","author":"S Carbone","year":"2019","unstructured":"Carbone S, Dixon DL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18(1):64.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1571_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684\u2013701.","journal-title":"Kidney Int"},{"issue":"10","key":"1571_CR7","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.ekir.2024.07.038","volume":"9","author":"TA Mavrakanas","year":"2024","unstructured":"Mavrakanas TA, Marsot A, Tsirella E, Rios N, Gritsas A, Suri RS. Canagliflozin pharmacokinetics at steady state in patients on maintenance hemodialysis. Kidney Int Rep. 2024;9(10):3049\u201352.","journal-title":"Kidney Int Rep."},{"issue":"3","key":"1571_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clinthera.2014.12.013","volume":"37","author":"D Devineni","year":"2015","unstructured":"Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610-28.e4.","journal-title":"Clin Ther"},{"issue":"9","key":"1571_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/jcph.506","volume":"55","author":"S Francke","year":"2015","unstructured":"Francke S, Mamidi RN, Solanki B, Scheers E, Jadwin A, Favis R, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061\u201372.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1571_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"1571_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1571_CR12","unstructured":"(FDA) AUSFaDA. T INVOKANA (canagliflozin) tablets\u2014FDA prescribing information. 2023 [cited; Available from: U https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204042s040lbl.pdf."},{"issue":"1","key":"1571_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231\u201344.","journal-title":"Kidney Int"},{"issue":"12","key":"1571_CR14","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513","volume":"23","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Carroll AK, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab. 2021;23(12):2632\u201342.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1571_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4663","volume":"33","author":"BCL Dias","year":"2019","unstructured":"Dias BCL, Fachi MM, de Campos ML, Degaut FLD, Peccinini RG, Pontarolo R. A new HPLC\u2013MS\/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomed Chromatogr. 2019;33(11):e4663.","journal-title":"Biomed Chromatogr"},{"issue":"3","key":"1571_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s13300-016-0174-y","volume":"7","author":"KT Baron","year":"2016","unstructured":"Baron KT, Macha S, Broedl UC, Nock V, Retlich S, Riggs M. Population pharmacokinetics and exposure-response (efficacy and safety\/tolerability) of empagliflozin in patients with type 2 diabetes. Diabetes Ther. 2016;7(3):455\u201371.","journal-title":"Diabetes Ther."},{"issue":"7","key":"1571_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/cpdd.885","volume":"10","author":"DJ Fediuk","year":"2021","unstructured":"Fediuk DJ, Zhou S, Dawra VK, Sahasrabudhe V, Sweeney K. Population pharmacokinetic model for ertugliflozin in healthy subjects and patients with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2021;10(7):696\u2013706.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"1571_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jcph.147","volume":"53","author":"MM Riggs","year":"2013","unstructured":"Riggs MM, Staab A, Seman L, MacGregor TR, Bergsma TT, Gastonguay MR, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol. 2013;53(10):1028\u201338.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1571_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40262-020-00956-1","volume":"60","author":"AB van der Aart-van der Beek","year":"2021","unstructured":"van der Aart-van der Beek AB, Koomen JV, Dekkers CCJ, Barbour SJ, Boulton DW, Gansevoort RT, et al. Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease. Clin Pharmacokinet. 2021;60(4):517\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1571_CR20","first-page":"42","volume":"2","author":"J-S van der Walt","year":"2013","unstructured":"van der Walt J-S, Hong Y, Zhang L, Pfister M, Boulton D, Karlsson M. A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment. CPT Pharmacomet Syst Pharmacol. 2013;2(5):42.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"issue":"2","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","volume":"55","author":"E Hoeben","year":"2016","unstructured":"Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A. Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2016;55(2):209\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1571_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/jcph.2196","volume":"63","author":"RC Penland","year":"2023","unstructured":"Penland RC, Melin J, Boulton DW, Tang W. Evaluation of the pharmacokinetics of dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes mellitus. J Clin Pharmacol. 2023;63(5):551\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1571_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cger.2015.04.003","volume":"31","author":"S Soenen","year":"2015","unstructured":"Soenen S, Rayner CK, Horowitz M, Jones KL. Gastric emptying in the elderly. Clin Geriatr Med. 2015;31(3):339\u201353.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"1571_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00002512-200219070-00005","volume":"19","author":"D O\u2019Mahony","year":"2002","unstructured":"O\u2019Mahony D, O\u2019Leary P, Quigley EMM. Aging and intestinal motility. Drugs Aging. 2002;19(7):515\u201327.","journal-title":"Drugs Aging"},{"issue":"3","key":"1571_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/ageing\/6.3.138","volume":"6","author":"CM Castleden","year":"1977","unstructured":"Castleden CM, Volans CN, Raymond K. The effect of ageing on drug absorption from the gut. Age Ageing. 1977;6(3):138\u201343.","journal-title":"Age Ageing"},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-319-32304-6_5","volume-title":"Medication-related falls in older people: causative factors and management strategies","author":"L Mallet","year":"2016","unstructured":"Mallet L. Pharmacology of drugs in aging. In: Huang AR, Mallet L, editors. Medication-related falls in older people: causative factors and management strategies. Cham: Springer International Publishing; 2016. p. 55\u201366."},{"issue":"10","key":"1571_CR27","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/bcp.14094","volume":"86","author":"AC Drenth-van Maanen","year":"2020","unstructured":"Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people\u2014how to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol. 2020;86(10):1921\u201330.","journal-title":"Br J Clin Pharmacol"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/978-1-4419-6999-6_58","volume-title":"Principles and practice of geriatric surgery","author":"NA Brown","year":"2011","unstructured":"Brown NA, Levine JL, Zenilman ME. Age-related changes in the gastrointestinal tract. In: Rosenthal RA, Zenilman ME, Katlic MR, editors. Principles and practice of geriatric surgery. New York: Springer New York; 2011. p. 711\u201327."},{"key":"1571_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","volume":"32","author":"H Iijima","year":"2015","unstructured":"Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2015;32:768\u201382.","journal-title":"Adv Ther"},{"issue":"4","key":"1571_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","volume":"18","author":"R Pollack","year":"2022","unstructured":"Pollack R, Cahn A. Sglt2 inhibitors and safety in older patients. Heart Fail Clin. 2022;18(4):635\u201343.","journal-title":"Heart Fail Clin"},{"issue":"2","key":"1571_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2019","unstructured":"Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care. 2019;43(2):468\u201375.","journal-title":"Diabetes Care"},{"key":"1571_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/978-3-031-65952-2_32","volume-title":"Manual of cardiovascular disease in women","author":"A Evelo","year":"2024","unstructured":"Evelo A, Leegwater E, Visser LE. Sex differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions of cardiovascular drugs. In: Maas AHEM, Gerdts E, editors. Manual of cardiovascular disease in women. Cham: Springer Nature Switzerland; 2024. p. 445\u201359."},{"issue":"2","key":"1571_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","volume":"42","author":"JB Schwartz","year":"2003","unstructured":"Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107\u201321.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1571_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diaclin.33.1.5","volume":"33","author":"V Valentine","year":"2015","unstructured":"Valentine V, Hinnen D. Clinical implications of canagliflozin treatment in patients with type 2 diabetes. Clin Diabetes. 2015;33(1):5\u201313.","journal-title":"Clin Diabetes"},{"issue":"13","key":"1571_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134248","volume":"12","author":"JJ Gorgojo-Martinez","year":"2023","unstructured":"Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Gald\u00f3n Sanz-Pastor A, C\u00e1rdenas-Salas J, Ant\u00f3n-Bravo T, Brito-Sanfiel M, et al. Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: the INTENSIFY study. J Clin Med. 2023;12(13):4248.","journal-title":"J Clin Med"},{"issue":"1","key":"1571_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/kidneydial3010005","volume":"3","author":"N Lameire","year":"2023","unstructured":"Lameire N. Renal mechanisms of diuretic resistance in congestive heart failure. Kidney Dial. 2023;3(1):56\u201372.","journal-title":"Kidney Dial"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01571-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:31Z","timestamp":1763168611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01571-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01571-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.J.E. is supported by an educational grant from Pfizer. TAM received speaker honoraria from Bayer, Novo Nordisk, and B\u00f6hringer Ingelheim and has served on advisory boards for B\u00f6hringer Ingelheim, Bayer, and Novo Nordisk outside the submitted work. He has also received a research grant from Astra Zeneca, Bayer, and Pfizer and operational grants from the Kidney Foundation of Canada, the Heart & Stroke foundation of Canada, and the Canadian Institute of Health Research. He is receiving salary support from the Fonds de Recherche Quebec Sant\u00e9 (Clinician Scholar Award) and is supported by a KRESCENT New Investigator Award. R.S.S. has received honoraria from Otsuka and Novo-Nordisk and carries out a leadership role in the Canadian Society of Nephrology, the Kidney Foundation of Canada, and at McGill University. A.M. is an editorial board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Both the studies included in the analysis were approved by McGill University Health Center Research Ethics Board (2022-8410) and Health Canada.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each patient before enrollment into the study. These studies were conducted in accordance with Good Clinical Practice guidelines and Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Data will be made available on reasonable request to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conceptualization: A.M., T.A.M., and R.S.S.; data curation: E.J.E. and A.G.; formal analysis: A.M.; visualization: A.M.; supervision, project administration, and validation: A.M. and T.A.M.; writing\u2014original draft: E.J.E.; and review and editing: E.J.E., T.A.M., A.G., R.S.S., and A.M.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}